Ingelvac® M. hyoRespiratory Vaccines, Timing Impact PCV2Type 2 porcine circovirus (PCV2) is now associated with several diseases, including postweaning multisystemic wasting syndrome (PMWS), reproductive disorders, porcine... Making M. hyo vaccination more flexibleBoehringer Ingelheim Vetmedica researchers reviewed and conducted an overall analysis of nine previous large-scale evaluations from five countries on... Fast onset for Myco controlVaccination against Mycoplasma is the most common vaccine administered to pigs, with over 60% of animals receiving the vaccine. Providing a high level... New technology in vaccine administrationSyringe and needle; needle and syringe. These two words have long gone togetherbut maybe not any more. Two companies have developed new technologies that... Health actions to maximize performanceWhen disease agents have entered the herd, intervention may become necessary. Once you've identified the agents, and evaluated the economic impact, a... Ingelvac HP-1 breaks new groundBoehringer Ingelheim Vetmedica, Inc. is happy to announce the introduction of a new single dose vaccine for Haemophilus parasuis. Ingelvac HP-1 is the... Keep what you have!Much attention is paid to breeding stock inventories when the quarterly USDA reports arrive. Will the herd expand and prices go down? Are gilt marketings... Ingelvac M.hyo optimizes immunity, protectionA recent collaborative study between research scientists at Boehringer Ingelheim and researchers at the University of Illinois confirmed Ingelvac M.hyo... Simple handling for Ingelvac M.hyoIngelvac M.hyo's unique adjuvant, Impran, provides for extended stimulation of the immune system. Made of an advanced bio-lipid, this adjuvant is a food... Vaccination delivers consistent results against MycoplasmaVaccination against Mycoplasma has demonstrated positive economic returns. Two-dose bacterins have consistently reduced the economic impact of Mycoplasma... |